• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Pre-Market Session

    12/16/22 8:07:12 AM ET
    $ADAG
    $BACK
    $EXAS
    $GH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Health Care
    Get the next $ADAG alert in real time by email

    Gainers

    • Exact Sciences (NASDAQ:EXAS) shares increased by 17.9% to $52.6 during Friday's pre-market session. The company's market cap stands at $9.3 billion.
    • IMAC Holdings (NASDAQ:BACK) shares increased by 15.71% to $0.28. The company's market cap stands at $9.2 million.
    • Adagene (NASDAQ:ADAG) shares moved upwards by 13.63% to $1.5. The market value of their outstanding shares is at $65.1 million.
    • Monopar Therapeutics (NASDAQ:MNPR) shares moved upwards by 12.45% to $2.98. The market value of their outstanding shares is at $38.3 million.
    • Rezolute (NASDAQ:RZLT) stock rose 10.73% to $1.65. The market value of their outstanding shares is at $60.7 million.
    • Prenetics Global (NASDAQ:PRE) stock rose 8.8% to $2.1. The market value of their outstanding shares is at $249.5 million.

    Losers

    • Guardant Health (NASDAQ:GH) shares declined by 32.7% to $27.79 during Friday's pre-market session. The market value of their outstanding shares is at $2.8 billion.
    • Scopus BioPharma (NASDAQ:SCPS) stock declined by 29.35% to $0.24. The company's market cap stands at $5.0 million.
    • Revelation Biosciences (NASDAQ:REVBU) stock decreased by 18.01% to $0.2.
    • Viveve Medical (NASDAQ:VIVE) shares decreased by 17.76% to $0.37. The market value of their outstanding shares is at $3.9 million.
    • MorphoSys (NASDAQ:MOR) stock decreased by 17.05% to $3.31. The company's market cap stands at $453.2 million.
    • Yumanity Therapeutics (NASDAQ:YMTX) stock decreased by 14.95% to $1.48. The company's market cap stands at $16.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADAG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADAG
    $BACK
    $EXAS
    $GH

    CompanyDatePrice TargetRatingAnalyst
    Guardant Health Inc.
    $GH
    2/20/2026$125.00 → $135.00Buy
    Canaccord Genuity
    Guardant Health Inc.
    $GH
    2/17/2026$120.00Outperform
    Robert W. Baird
    Prenetics Global Limited
    $PRE
    2/11/2026$36.00Buy
    Roth Capital
    Exact Sciences Corporation
    $EXAS
    1/20/2026$105.00Outperform → Neutral
    Mizuho
    Monopar Therapeutics Inc.
    $MNPR
    1/9/2026$115.00Overweight
    Morgan Stanley
    Guardant Health Inc.
    $GH
    1/5/2026$105.00Outperform → In-line
    Evercore ISI
    Exact Sciences Corporation
    $EXAS
    1/5/2026$105.00Outperform → In-line
    Evercore ISI
    Rezolute Inc.
    $RZLT
    12/11/2025$2.00Buy → Hold
    Craig Hallum
    More analyst ratings

    $ADAG
    $BACK
    $EXAS
    $GH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Prenetics Launches IM8 Daily Ultimate Essentials PRO — A Clinical Formula with Two New Flavours

    Up to 733% Greater Potency Across 11 Key Nutrients, Including New Saffron Nootropic and Bioactive Vitamin Forms Two New Flavours — Mango + Passionfruit and Lemon + Orange Same Price for New and Existing Customers Full Supplement Facts Available at im8health.com/products/essentials NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced the launch of Daily Ultimate Essentials PRO, a new clinical-grade version of its flagship daily health supplement under the IM8 Health brand. Alongside the reformulated product, Pren

    2/23/26 9:00:00 AM ET
    $PRE
    Blank Checks
    Finance

    Exact Sciences Stockholders Approve Acquisition by Abbott

    Exact Sciences Corporation (NASDAQ:EXAS) ("Exact Sciences"), a leading provider of cancer screening and diagnostic tests, today announced that its stockholders voted to approve the proposed acquisition of Exact Sciences by Abbott (NYSE:ABT) at the special meeting of stockholders held earlier today. At the special meeting, preliminary results showed that more than 99% of the votes cast, representing approximately 67% of the total outstanding shares of Exact Sciences common stock as of the January 9, 2026 record date for the special meeting, were voted in favor of the transaction. Final voting results from the special meeting will be reported by Exact Sciences in a Current Report on Form 8‑

    2/20/26 4:05:00 PM ET
    $ABT
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook

    Fourth quarter 2025 revenue growth of 39% broadly driven by strong performance across Oncology and Screening Expects full year 2026 total revenue to grow in the range of 27% to 30% year-over-year Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights For the three-month period ended December 31, 2025, as compared to the same period of 2024: Reported total revenue of $281.3 million, an increase of 39%, driven by: Oncology revenue of $189.9 million, an increase of 30%, and approximately 79,000 oncology tests, an increase of 38% Biop

    2/19/26 4:05:00 PM ET
    $GH
    Medical Specialities
    Health Care

    $ADAG
    $BACK
    $EXAS
    $GH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Vu Quan Anh bought $104,925 worth of shares (1,500 units at $69.95) (SEC Form 4)

    4 - Monopar Therapeutics (0001645469) (Issuer)

    12/29/25 12:15:31 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hogenhuis Wladimir bought $9,548 worth of shares (5,650 units at $1.69), increasing direct ownership by 5% to 119,675 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    12/17/25 4:14:55 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Roberts Brian Kenneth bought $47,600 worth of shares (28,000 units at $1.70), increasing direct ownership by 10% to 308,352 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    12/17/25 4:13:53 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    $BACK
    $EXAS
    $GH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 30, 2024 - FDA Roundup: July 30, 2024

    For Immediate Release: July 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA is announcing the fiscal year (FY) 2025 user fee rates for importers approved to participate in the Voluntary Qualified Importer Program (VQIP) and accreditation and certification bodies interested in participating in the Accredited Third-Party C

    7/30/24 3:38:18 PM ET
    $GH
    Medical Specialities
    Health Care

    May 28, 2021 - FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy

    For Immediate Release: May 28, 2021 Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy. This is the first approved targeted therapy for tumors with any KRAS mutation, which accounts for ap

    5/28/21 1:05:48 PM ET
    $AMGN
    $GH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities

    May 21, 2021 - FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer

    For Immediate Release: May 21, 2021 Today, the U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The FDA also approved the Guardant360 CDx (Guardant Health Inc.) as a companion diagnostic for Ry

    5/21/21 12:50:51 PM ET
    $JNJ
    $GH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    $ADAG
    $BACK
    $EXAS
    $GH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity reiterated coverage on Guardant Health with a new price target

    Canaccord Genuity reiterated coverage of Guardant Health with a rating of Buy and set a new price target of $135.00 from $125.00 previously

    2/20/26 8:00:16 AM ET
    $GH
    Medical Specialities
    Health Care

    Robert W. Baird initiated coverage on Guardant Health with a new price target

    Robert W. Baird initiated coverage of Guardant Health with a rating of Outperform and set a new price target of $120.00

    2/17/26 8:18:22 AM ET
    $GH
    Medical Specialities
    Health Care

    Roth Capital initiated coverage on Prenetics Group Ltd. with a new price target

    Roth Capital initiated coverage of Prenetics Group Ltd. with a rating of Buy and set a new price target of $36.00

    2/11/26 7:52:37 AM ET
    $PRE
    Blank Checks
    Finance

    $ADAG
    $BACK
    $EXAS
    $GH
    SEC Filings

    View All

    SEC Form 8-K filed by Exact Sciences Corporation

    8-K - EXACT SCIENCES CORP (0001124140) (Filer)

    2/20/26 4:55:01 PM ET
    $EXAS
    Medical Specialities
    Health Care

    SEC Form S-8 filed by Guardant Health Inc.

    S-8 - Guardant Health, Inc. (0001576280) (Filer)

    2/20/26 9:05:55 AM ET
    $GH
    Medical Specialities
    Health Care

    SEC Form 10-K filed by Guardant Health Inc.

    10-K - Guardant Health, Inc. (0001576280) (Filer)

    2/19/26 5:14:48 PM ET
    $GH
    Medical Specialities
    Health Care

    $ADAG
    $BACK
    $EXAS
    $GH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mignone Roberto converted options into 264 shares, increasing direct ownership by 7% to 4,223 units (SEC Form 4)

    4 - Guardant Health, Inc. (0001576280) (Issuer)

    2/23/26 5:47:02 PM ET
    $GH
    Medical Specialities
    Health Care

    Director Hidalgo Medina Manuel converted options into 232 shares, increasing direct ownership by 18% to 1,493 units (SEC Form 4)

    4 - Guardant Health, Inc. (0001576280) (Issuer)

    2/18/26 4:27:49 PM ET
    $GH
    Medical Specialities
    Health Care

    Director Tariq Musa converted options into 250 shares, increasing direct ownership by 3% to 8,493 units (SEC Form 4)

    4 - Guardant Health, Inc. (0001576280) (Issuer)

    2/17/26 6:31:43 PM ET
    $GH
    Medical Specialities
    Health Care

    $ADAG
    $BACK
    $EXAS
    $GH
    Leadership Updates

    Live Leadership Updates

    View All

    Formula 1 Phenom Ollie Bearman Joins Prenetics' IM8 Health as Global Ambassador and Shareholder

    Ollie Bearman becomes the latest elite athlete to invest in NASDAQ:PRE, underscoring a deep belief in the brand's mission and products.IM8, co-founded by David Beckham, continues to attract top-tier athletes who prioritize scientifically validated and trusted nutritional support.IM8 has become one of the fastest-growing supplement brands globally, achieving an extraordinary US$100 million in Annual Recurring Revenue in just 11 months from launch.Bearman's rapid rise – including a historic points-scoring Ferrari debut at just 18—cements his reputation as one of motorsport's brightest young talents. NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE), a leading

    2/13/26 8:00:00 AM ET
    $PRE
    Blank Checks
    Finance

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    $ADAG
    $BACK
    $EXAS
    $GH
    Financials

    Live finance-specific insights

    View All

    Prenetics Reports Record Q4 and FY 2025 Results: IM8 Achieves $120M ARR¹ in 12 Months, Revenue Surges 480% YoY

    Total Revenue Increased 480% to $92.4 million for Full Year 2025, Q4 Revenue reached $36.6 millionIM8 Reaches $10 Million in Monthly Revenue in December 2025, Achieving $120M ARR MilestoneStrategic Transformation Completed with Divestitures and Focus on IM8 Total Adjusted Liquidity2 of Approximately $171 Million Following Sale of Insighta Stake to Tencent, with Zero DebtCompany to Host Earnings Call on February 18, 2026, at 10:00 a.m. ET and latest investor deck can be found at https://ir.prenetics.com NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading consumer health sciences company and parent of the IM8 premium he

    2/18/26 9:11:26 AM ET
    $PRE
    Blank Checks
    Finance

    Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results

    Fourth quarter and 2025 highlights Total fourth quarter revenue of $878 million, an increase of 23% on a reported and core revenue basis, with Screening revenue of $695 million and Precision Oncology revenue of $183 million Total 2025 revenue of $3.25 billion, an increase of 18% on a reported and core revenue basis, with Screening revenue of $2.53 billion and Precision Oncology revenue of $717 million Operating cash flow was $491 million and free cash flow was $357 million for the full-year 2025, an improvement of 133% and 379%, respectively Net loss was $208 million and adjusted EBITDA was $400 million for the full-year 2025, an improvement of $821 million and $77 million, resp

    2/13/26 4:05:00 PM ET
    $EXAS
    Medical Specialities
    Health Care

    Prenetics to Report Q4 and Full Year 2025 Financial Results on Feb 18, 2026 and Host Earnings Conference Call

    NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced it will release financial results for the fourth quarter and full year 2025 ended December 31, 2025 before market open on Wednesday, February 18, 2026. The Company will also hold its earnings conference call the same day at 10:00 a.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with analysts. Date:Wednesday, February 18, 2026Time:10:00 a.m. Eastern TimeDial-in:1-877-425-9470International Dial-in:1-201-389-0878

    2/11/26 8:00:00 AM ET
    $PRE
    Blank Checks
    Finance

    $ADAG
    $BACK
    $EXAS
    $GH
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at Monopar Therapeutics Inc. on Jun 21 Indicate?

    Monopar Therapeutics Inc. has recently seen notable insider activity, with Chief Operating Officer Cittadine Andrew purchasing $25,574 worth of shares on June 21st, 2024. This purchase, comprising 32,508 units at $0.79, increased Cittadine's direct ownership by 21% to 186,132 units as reported in the SEC Form 4. When analyzing this transaction alongside other recent insider activities within the company, interesting patterns and trends start to emerge. Looking back, Cittadine Andrew has been consistently adding to his position in Monopar Therapeutics Inc. over the past few months, showcasing a strong conviction in the company's future prospects. On May 31st, Cittadine Andrew made a substan

    6/22/24 8:00:00 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    $BACK
    $EXAS
    $GH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Monopar Therapeutics Inc.

    SC 13D/A - Monopar Therapeutics (0001645469) (Subject)

    12/17/24 5:01:42 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Rezolute Inc.

    SC 13G/A - Rezolute, Inc. (0001509261) (Subject)

    11/14/24 6:59:50 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Prenetics Global Limited

    SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

    11/14/24 12:30:15 PM ET
    $PRE
    Blank Checks
    Finance